MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329003 | Name: Edaravone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Edaravone, also known as Radicut and MCI-186, is a novel potent free radical scavenger that has been clinically used to reduce the neuronal damage following ischemic stroke. Edaravone exerts neuroprotective effects by inhibiting endothelial injury and by ameliorating neuronal damage in brain ischemia. Edaravone provides the desirable features of NOS: it increases eNOS (beneficial NOS for rescuing ischemic stroke) and decreases nNOS and iNOS (detrimental NOS).

Chemical Structure

Edaravone
Edaravone
CAS#89-25-8

Theoretical Analysis

MedKoo Cat#: 329003

Name: Edaravone

CAS#: 89-25-8

Chemical Formula: C10H10N2O

Exact Mass: 174.0793

Molecular Weight: 174.20

Elemental Analysis: C, 68.95; H, 5.79; N, 16.08; O, 9.18

Price and Availability

Size Price Availability Quantity
5g USD 250.00 2 Weeks
25g USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Methylphenylpyrazolone; Monopyrazolone; Edaravone; Norantipyrine; Norphenazone; Radicut; MCI-186; MCI186; MCI 186; NSC-2629; NSC2629; NSC 2629
IUPAC/Chemical Name
5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one
InChi Key
QELUYTUMUWHWMC-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3
SMILES Code
O=C1CC(C)=NN1C2=CC=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Edaravone is a strong novel free radical scavenger.
In vitro activity:
To explore the effect of EDA (edaravone) on LPS-stimulated phenotypic transformation of microglia, the expression of Arg-1 and TNF-α was detected by ELISA and RT-PCR (Figures 5A,B). The results showed that immunoreactivity of M1 marker (TNF-α) was in a high level and that of M2 marker (Arg-1) was low in LPS-treated cultures. However, TNF-α and Arg-1 expressions were significantly reversed in the EDA groups. This result suggested that EDA shifted the inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. Reference: Front Pharmacol. 2021; 12: 691773. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201503/
In vivo activity:
Cd-induced neurotoxicity was observed in position navigation training (days 1–6, Fig. 2B-C), as it impaired the spatial exploration and memory abilities of mice in the Morris water maze test, with prolonged escape latency compared to controls (Fig. 2B and C). However, Eda (edaravone) treatment eliminated Cd-induced neurotoxicity and improved learning and memory deficits in mice. Reference: Neurotoxicology. 2021 Jun 24;86:1-9. https://pubmed.ncbi.nlm.nih.gov/34174317/
Solvent mg/mL mM
Solubility
DMF:PBS (pH 7.2) (1:9) 0.1 0.57
Ethanol 9.5 54.53
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 174.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Li J, Dai X, Zhou L, Li X, Pan D. Edaravone Plays Protective Effects on LPS-Induced Microglia by Switching M1/M2 Phenotypes and Regulating NLRP3 Inflammasome Activation. Front Pharmacol. 2021 May 31;12:691773. doi: 10.3389/fphar.2021.691773. PMID: 34135761; PMCID: PMC8201503. 2. Wu HT, Yu Y, Li XX, Lang XY, Gu RZ, Fan SR, Fang X, Bai JP, Lan R, Qin XY. Edaravone attenuates H2O2 or glutamate-induced toxicity in hippocampal neurons and improves AlCl3/D-galactose induced cognitive impairment in mice. Neurotoxicology. 2021 Jul;85:68-78. doi: 10.1016/j.neuro.2021.05.005. Epub 2021 May 15. PMID: 34004234. 3. Fan SR, Ren TT, Yun MY, Lan R, Qin XY. Edaravone attenuates cadmium-induced toxicity by inhibiting oxidative stress and inflammation in ICR mice. Neurotoxicology. 2021 Jun 24;86:1-9. doi: 10.1016/j.neuro.2021.06.003. Epub ahead of print. PMID: 34174317. 4. Xiao C, Du M, Liu Y, Yu Y, Yang J. Edaravone attenuates smoke inhalation injury in rats by the Notch pathway. Am J Transl Res. 2021 May 15;13(5):4712-4718. PMID: 34150051; PMCID: PMC8205801.
In vitro protocol:
1. Li J, Dai X, Zhou L, Li X, Pan D. Edaravone Plays Protective Effects on LPS-Induced Microglia by Switching M1/M2 Phenotypes and Regulating NLRP3 Inflammasome Activation. Front Pharmacol. 2021 May 31;12:691773. doi: 10.3389/fphar.2021.691773. PMID: 34135761; PMCID: PMC8201503. 2. Wu HT, Yu Y, Li XX, Lang XY, Gu RZ, Fan SR, Fang X, Bai JP, Lan R, Qin XY. Edaravone attenuates H2O2 or glutamate-induced toxicity in hippocampal neurons and improves AlCl3/D-galactose induced cognitive impairment in mice. Neurotoxicology. 2021 Jul;85:68-78. doi: 10.1016/j.neuro.2021.05.005. Epub 2021 May 15. PMID: 34004234.
In vivo protocol:
1. Fan SR, Ren TT, Yun MY, Lan R, Qin XY. Edaravone attenuates cadmium-induced toxicity by inhibiting oxidative stress and inflammation in ICR mice. Neurotoxicology. 2021 Jun 24;86:1-9. doi: 10.1016/j.neuro.2021.06.003. Epub ahead of print. PMID: 34174317. 2. Xiao C, Du M, Liu Y, Yu Y, Yang J. Edaravone attenuates smoke inhalation injury in rats by the Notch pathway. Am J Transl Res. 2021 May 15;13(5):4712-4718. PMID: 34150051; PMCID: PMC8205801.
1: Bailly C. Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers. Int Immunopharmacol. 2019 Oct 26;77:105967. doi: 10.1016/j.intimp.2019.105967. [Epub ahead of print] Review. PubMed PMID: 31670091. 2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548729/ PubMed PMID: 31644038. 3: Pharmacoeconomic Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of Amyotrophic Lateral Sclerosis (ALS) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK542526/ PubMed PMID: 31211530. 4: CADTH Canadian Drug Expert Committee Recommendation: Edaravone (Radicava — Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Mar. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK542405/ PubMed PMID: 31206289. 5: Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK542359/ PubMed PMID: 31206286. 6: Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019 Mar;39(2):733-748. doi: 10.1002/med.21528. Epub 2018 Aug 12. Review. PubMed PMID: 30101496. 7: Bhandari R, Kuhad A, Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc). 2018 Jun;54(6):349-360. doi: 10.1358/dot.2018.54.6.2828189. Review. PubMed PMID: 29998226. 8: Matsumoto S, Murozono M, Kanazawa M, Nara T, Ozawa T, Watanabe Y. Edaravone and cyclosporine A as neuroprotective agents for acute ischemic stroke. Acute Med Surg. 2018 May 17;5(3):213-221. doi: 10.1002/ams2.343. eCollection 2018 Jul. Review. PubMed PMID: 29988669; PubMed Central PMCID: PMC6028804. 9: Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion. Am J Manag Care. 2018 Apr;24(9 Suppl):S175-S186. Review. PubMed PMID: 29693363. 10: Dash RP, Babu RJ, Srinivas NR. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics. Clin Pharmacokinet. 2018 Nov;57(11):1385-1398. doi: 10.1007/s40262-018-0655-4. Review. PubMed PMID: 29682695. 11: Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr. 2018 Jan;62(1):20-38. doi: 10.3164/jcbn.17-62. Epub 2017 Nov 11. Review. PubMed PMID: 29371752; PubMed Central PMCID: PMC5773834. 12: Ali ZK, Baker DE. Formulary Drug Review: Edaravone. Hosp Pharm. 2017 Dec;52(11):732-736. doi: 10.1177/0018578717734877. Epub 2017 Oct 9. Review. PubMed PMID: 29276251; PubMed Central PMCID: PMC5735759. 13: Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holmøy T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH. July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):471-474. doi: 10.1080/21678421.2017.1369125. Epub 2017 Oct 4. Review. PubMed PMID: 28975816. 14: Maragakis NJ. What can we learn from the edaravone development program for ALS? Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):98-103. doi: 10.1080/21678421.2017.1361446. Review. PubMed PMID: 28872911. 15: Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):5-10. doi: 10.1080/21678421.2017.1353101. Review. PubMed PMID: 28872907. 16: Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother. 2017 May;18(7):735-738. doi: 10.1080/14656566.2017.1319937. Review. PubMed PMID: 28406335. 17: Masuda T, Shimazawa M, Hara H. Retinal Diseases Associated with Oxidative Stress and the Effects of a Free Radical Scavenger (Edaravone). Oxid Med Cell Longev. 2017;2017:9208489. doi: 10.1155/2017/9208489. Epub 2017 Jan 18. Review. PubMed PMID: 28194256; PubMed Central PMCID: PMC5286467. 18: Yamamoto Y. Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite. J Clin Biochem Nutr. 2017 Jan;60(1):49-54. doi: 10.3164/jcbn.16-63. Epub 2016 Nov 12. Review. PubMed PMID: 28163382; PubMed Central PMCID: PMC5281530. 19: Miyaji Y, Yoshimura S, Sakai N, Yamagami H, Egashira Y, Shirakawa M, Uchida K, Kageyama H, Tomogane Y. Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry. Neurol Med Chir (Tokyo). 2015;55(3):241-7. doi: 10.2176/nmc.ra.2014-0219. Epub 2015 Feb 20. Review. PubMed PMID: 25739433; PubMed Central PMCID: PMC4533339. 20: Wu S, Sena E, Egan K, Macleod M, Mead G. Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. Int J Stroke. 2014 Jan;9(1):101-6. doi: 10.1111/ijs.12163. Epub 2013 Oct 22. Review. PubMed PMID: 24148907.

View History

BMS-554417

BMS-554417

HAC-Y6

HAC-Y6

Z060228

Z060228

Pactamycin

Pactamycin